Craft

eTheRNA

Total Funding

$66.3 M

eTheRNA Summary

Company Summary

Overview
eTheRNA immunotherapies is a biotech company developing immuno-oncology therapies based on its APC-activating messenger RNA platform. Its mRNA-based TriMix technology boosts dendritic cells and mobilizes the immune system to attack cancer cells through inducing a directed cytotoxic T-cell response.
Type
Private
Status
Active
Founded
2013
HQ
Antwerp, BE | view all locations
Website
https://www.etherna.be/
Cybersecurity rating
Sectors

Key People

  • Diane van Hoorick

    Diane van Hoorick, VP Translational Development

    • Russel G. Greig, Chairman of the Board

      • Chris Buyse, Director

        • John de Koning

          John de Koning, Director

          LocationsView all

          4 locations detected

          • Antwerp, Vlaams Gewest HQ

            Belgium

            Galileilaan 19

          • Boston, MA

            United States

            20 Park Plaza, Suite 1005

          • Ghent, Vlaams Gewest

            Belgium

            Frieda Saeysstraat 1B, 3rd floor

          • Hong Kong, Hong Kong Island

            Hong Kong

            Unit 605-07, 6/F Wing on Center, 111 Connaught Road

          Footer menu